📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
143 announcements match the current filters (relevance ≥ 5).
Jubilant Ingrevia Q4 FY26 PAT Jumps 17% YoY to ₹86 Cr; Final Dividend of ₹2.50 Declared
Jubilant Ingrevia reported a strong Q4 FY26 with revenue growing 12% YoY to ₹1,179 crore, marking its highest revenue in 14 quarters. The company's PAT rose 17% YoY to ₹86 crore, supported by a 10% volume growth and effective cost pass-through despite Middle East supply chain disruptions. The Specialty Chemicals segment remained a key driver with 27% EBITDA margins, while the Nutrition segment saw a robust 21% YoY revenue growth. Management has signaled a positive outlook for FY27, focusing on CDMO expansion and the integration of the Remidex Pharma acquisition.
Key Highlights
Q4 FY26 Revenue increased 12% YoY to ₹1,179 crore with EBITDA rising 11% YoY to ₹172 crore.
Specialty Chemicals segment reported FY26 EBITDA growth of 21% with margins holding steady at 27%.
Net Debt/EBITDA improved to 0.99x as net debt was reduced by 11% during the financial year.
Board recommended a final dividend of ₹2.50 per share, bringing the total FY26 dividend to ₹5 per share.
Successfully commissioned the Bharuch CDMO plant and completed the acquisition of Remidex Pharma to boost Human Nutrition.
👀 What to Watch
Investors should take note of the consistent volume growth and the successful shift towards high-margin Specialty Chemicals and CDMO segments. The improving balance sheet and healthy dividend payout make it a strong candidate for long-term portfolios in the chemical space.
Jubilant Ingrevia Recommends 250% Final Dividend of Rs 2.50 Per Share for FY26
Jubilant Ingrevia Limited has announced a final dividend of Rs 2.50 per equity share, representing a 250% payout on its Re 1 face value for the financial year ended March 31, 2026. The company has established July 24, 2026, as the record date for determining eligibility, with the payout expected within 30 days of the AGM. Alongside the dividend, the board confirmed the re-appointment of M/s J.K. Kabra & Co. as Cost Auditors for the 2026-27 fiscal year. This move signals a stable financial outlook and a consistent shareholder reward policy.
Key Highlights
Recommended a final dividend of 250% amounting to Rs 2.50 per equity share of Re 1 face value
Fixed Friday, July 24, 2026, as the record date for the purpose of final dividend payment
Re-appointed M/s J.K. Kabra & Co. as Cost Auditors for the financial year 2026-27
The dividend payout is subject to shareholder approval at the upcoming Annual General Meeting
👀 What to Watch
Investors seeking dividend income should ensure they hold the shares before the record date of July 24, 2026. The 250% dividend payout indicates a healthy cash flow position and management's commitment to returning value to shareholders.
Jubilant Ingrevia Recommends 250% Final Dividend of Rs 2.50 per Share
Jubilant Ingrevia Limited has recommended a final dividend of Rs 2.50 per equity share (250% of face value) for the financial year ended March 31, 2026. The company has fixed July 24, 2026, as the record date to determine shareholder eligibility for this payout. Additionally, the Board has approved the re-appointment of M/s J.K. Kabra & Co. as the Cost Auditors for the 2026-27 financial year. The dividend payment is subject to shareholder approval at the upcoming Annual General Meeting.
Key Highlights
Recommended final dividend of 250% amounting to Rs 2.50 per equity share of Re 1 face value
Record date for dividend eligibility set for Friday, July 24, 2026
Re-appointment of M/s J.K. Kabra & Co. as Cost Auditors for FY 2026-27
Dividend to be paid within 30 days from the date of the Annual General Meeting
👀 What to Watch
Investors interested in the dividend should ensure they hold the shares before the record date of July 24, 2026. The re-appointment of auditors suggests stability in the company's internal financial controls.
Jubilant Ingrevia Recommends 250% Final Dividend; Sets Record Date for July 24, 2026
Jubilant Ingrevia's Board has recommended a final dividend of Rs. 2.50 per equity share (250% of face value) for the financial year ended March 31, 2026. The company has fixed July 24, 2026, as the record date to determine eligibility for this payout. The dividend is subject to shareholder approval at the upcoming Annual General Meeting and will be paid within 30 days of the meeting. Additionally, the company has re-appointed M/s J.K. Kabra & Co. as Cost Auditors for the 2026-27 financial year.
Key Highlights
Recommended final dividend of Rs. 2.50 per equity share of Re. 1 face value (250%)
Record date for dividend eligibility fixed as Friday, July 24, 2026
Dividend payment to be completed within 30 days from the date of the Annual General Meeting
Re-appointment of M/s J.K. Kabra & Co. as Cost Auditors for FY 2026-27 approved
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date, which is typically one working day prior to the July 24 record date.
Jubilant Ingrevia Recommends Final Dividend of Rs 2.50 Per Share for FY 2025-26
Jubilant Ingrevia Limited has recommended a final dividend of Rs 2.50 per equity share (250% of face value) for the financial year ended March 31, 2026. The company has fixed July 24, 2026, as the record date to determine eligibility for the dividend payout. The board also approved the re-appointment of M/s J.K. Kabra & Co. as Cost Auditors for the 2026-27 fiscal year. This dividend is subject to shareholder approval at the upcoming Annual General Meeting.
Key Highlights
Recommended a final dividend of Rs 2.50 per equity share of face value Re 1 each (250%).
Fixed July 24, 2026, as the record date for the purpose of final dividend payment.
Dividend to be paid or dispatched within 30 days from the date of the Annual General Meeting.
Re-appointed M/s J.K. Kabra & Co. as Cost Auditors for the financial year 2026-27.
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the record date of July 24, 2026. The dividend yield should be calculated against the current market price to assess its attractiveness relative to peers.
Jubilant Ingrevia Recommends 250% Final Dividend of Rs 2.50 Per Share for FY26
Jubilant Ingrevia's Board has recommended a final dividend of Rs 2.50 per equity share (250% of face value) for the financial year ended March 31, 2026. The company has fixed July 24, 2026, as the record date to determine shareholder eligibility for this payout. Additionally, the Board approved the re-appointment of M/s J.K. Kabra & Co. as Cost Auditors for the upcoming fiscal year 2026-27. The dividend payment is contingent upon approval by shareholders at the Annual General Meeting.
Key Highlights
Recommended a final dividend of 250% or Rs 2.50 per equity share of Re 1 face value for FY 2025-26.
Fixed Friday, July 24, 2026, as the record date for the purpose of final dividend payment.
Approved the re-appointment of M/s J.K. Kabra & Co. as Cost Auditors for the financial year 2026-27.
The dividend will be paid or dispatched within 30 days from the date of the Annual General Meeting.
👀 What to Watch
Investors seeking dividend income should ensure they hold the stock before the record date of July 24, 2026. While the dividend is positive, investors should also analyze the full FY26 financial results to assess the company's growth trajectory.
Jubilant Pharmova Subsidiary Receives Rs 107.89 Cr Income Tax Adjustment Order
Jubilant Pharmova's step-down subsidiary, Jubilant Generics Limited (JGL), has received a tax order for FY 2022-23 involving adjustments of Rs 107.89 crores. The adjustments primarily stem from transfer pricing issues, which the company claims ignore its previous contentions. While the company is filing an appeal and expects relief, it has already identified a reduction in Deferred Tax Assets by Rs 37.70 crores. Management does not anticipate any other material financial implications following the redressal process.
Key Highlights
Income Tax Department issued an order for FY 23 making tax adjustments of Rs 107.89 crores.
Adjustments are primarily related to transfer pricing disputes within the subsidiary Jubilant Generics Limited.
The company has reported a reduction in Deferred Tax Assets (DTA) amounting to Rs 37.70 crores.
JGL is in the process of filing an appeal before the Commissioner of Income Tax (Appeals) and the Advance Pricing Authority.
Management expects the impugned tax adjustments to be deleted post-adjudication.
👀 What to Watch
Investors should monitor the outcome of the appeal process as tax disputes can be prolonged, though the immediate cash flow impact appears limited. The Rs 37.70 crore reduction in Deferred Tax Assets is a notable accounting impact to consider in the near term.
Jubilant Pharmova Appoints Ashish Mukkirwar as CFO and Priyavrat Bhartia as MD
Jubilant Pharmova is undergoing a significant leadership transition with the appointment of Mr. Ashish Mukkirwar as CFO (effective May 23, 2026) and Mr. Priyavrat Bhartia as Managing Director (effective June 1, 2026). Mr. Mukkirwar, an IIM Kolkata alumnus, joins from Glenmark Pharmaceuticals where he served as Group VP & CFO for Global Formulations. The outgoing CFO, Mr. Arun Kumar Sharma, will transition into an advisory role for the Chairmen after relinquishing his post on May 22, 2026. These appointments bring seasoned pharmaceutical industry expertise to the company's top management.
Key Highlights
Mr. Ashish Mukkirwar appointed as CFO and KMP effective May 23, 2026, bringing over 20 years of experience.
Mr. Priyavrat Bhartia to take charge as Managing Director of the company starting June 1, 2026.
Outgoing CFO Mr. Arun Kumar Sharma moves to a new role as Advisor to the Chairmen.
New CFO has a strong pedigree, previously holding senior roles at Glenmark Pharmaceuticals, Moelis & Company, and UBS Investment Banking.
👀 What to Watch
Investors should view this as a strategic move to strengthen leadership with experienced professionals from the pharma sector. Monitor for any changes in capital allocation or M&A strategy under the new leadership team.
Jubilant Pharmova Appoints Ashish Mukkirwar as CFO; Arun Kumar Sharma Transitions to Advisory Role
Jubilant Pharmova has announced a leadership transition where Mr. Ashish Mukkirwar will take over as Chief Financial Officer effective May 23, 2026. He succeeds Mr. Arun Kumar Sharma, who is stepping down from the CFO position to serve as an Advisor to the Chairmen. Mr. Mukkirwar brings over 20 years of experience, including a significant tenure at Glenmark Pharmaceuticals as Group VP & CFO of Global Formulations. The transition appears orderly as the outgoing CFO remains within the organization in a strategic capacity.
Key Highlights
Mr. Ashish Mukkirwar appointed as CFO and Key Managerial Personnel effective May 23, 2026
Outgoing CFO Mr. Arun Kumar Sharma to transition to Advisor to the Chairmen role from May 22, 2026
New CFO has over 20 years of experience in corporate finance, M&A, and strategy at Glenmark and UBS
The Board meeting for these approvals concluded at 02:10 P.M. on May 22, 2026
👀 What to Watch
Investors should view this as a routine but important leadership transition; monitor if the new CFO introduces any changes to the company's capital allocation or financial reporting strategies.
Jubilant Pharmova FY26 Revenue Rises 14% to Rs 8,280 Cr; Rs 5 Dividend Declared
Jubilant Pharmova reported a solid 14% YoY revenue growth for FY26, reaching Rs 8,280 crore, led by a 38% surge in the CDMO Sterile Injectables segment. Annual EBITDA grew 8% to Rs 1,326 crore, although Q4 margins faced pressure due to a temporary shutdown at the Montreal facility for FDA remediation. The company has successfully onboarded a major oncology product at its Spokane facility and proposed a dividend of Rs 5 per share. Management anticipates margin strengthening from H2'FY27 as production at Montreal stabilizes.
Key Highlights
FY26 Revenue increased 14% YoY to Rs 8,280 Cr, with Normalised PAT growing 7% to Rs 442 Cr.
CDMO Sterile Injectables revenue grew 38% to Rs 1,755 Cr, driven by the ramp-up of Line 3 at the Spokane facility.
Ruby-Fill install base in the Radiopharma segment grew by 35% in FY26 compared to 21% in FY25.
The Board proposed a dividend of Rs 5 per equity share for the financial year ended March 31, 2026.
Net Debt to EBITDA ratio remained stable at 1.3x as of March 2026 despite ongoing growth investments.
👀 What to Watch
Investors should focus on the successful onboarding of the large oncology product and the expected margin recovery in H2'FY27. The integration of API and Drug Discovery into Jubilant Biosys is a positive move for long-term operational efficiency.
Jubilant Pharmova Appoints Ashish Mukkirwar as CFO; Arun Kumar Sharma Moves to Advisor Role
Jubilant Pharmova has announced a leadership transition with Mr. Ashish Mukkirwar appointed as the new Chief Financial Officer effective May 23, 2026. He succeeds Mr. Arun Kumar Sharma, who will transition into a new role as Advisor to the Chairmen after serving as the CFO. Mr. Mukkirwar brings over 20 years of experience, having previously served as Group VP & CFO of Global Formulations at Glenmark Pharmaceuticals. This transition appears to be a planned succession, maintaining internal continuity while bringing in external expertise from a larger industry peer.
Key Highlights
Mr. Ashish Mukkirwar appointed as CFO and Key Managerial Personnel effective May 23, 2026
Outgoing CFO Mr. Arun Kumar Sharma moves to an Advisor role to the Chairmen effective May 22, 2026
New CFO joins from Glenmark Pharmaceuticals with over 20 years of experience in finance, M&A, and strategy
Mr. Mukkirwar is an IIM Calcutta alumnus with prior investment banking experience at UBS and Moelis & Company
👀 What to Watch
Investors should view this as a positive leadership update given the appointee's strong pedigree in the pharmaceutical sector. Monitor the next few quarterly calls for any shifts in financial strategy or capital allocation priorities under the new CFO.
Jubilant Pharmova Re-appoints MD and Joint MD for 3-Year Terms Effective June 2026
The Board of Jubilant Pharmova has approved the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director. Both appointments are for a three-year duration starting June 1, 2026, pending shareholder approval. The leaders have been part of the board since 2017 and in their current executive roles since June 2023. This move ensures continuity in the company's strategic management and long-term vision.
Key Highlights
Re-appointment of Priyavrat Bhartia as MD for a 3-year term effective June 1, 2026.
Re-appointment of Arjun Shanker Bhartia as Joint MD for a 3-year term effective June 1, 2026.
Priyavrat Bhartia brings 29 years of industry experience with an MBA from Stanford University.
Arjun Shanker Bhartia is a Brown University graduate with prior strategy experience at Bain & Company.
👀 What to Watch
Investors should view this as a sign of management stability and continuity in strategic direction. No immediate action is required as these are expected re-appointments of the promoter-led management team.
Jubilant Pharmova Re-appoints MD and Joint MD for 3-Year Terms Effective June 2026
The Board of Jubilant Pharmova has approved the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director. Both appointments are for a further term of three years, starting June 1, 2026, and are subject to shareholder approval. Mr. Priyavrat Bhartia brings 29 years of industry experience, while Mr. Arjun Shanker Bhartia has a background in strategic consulting with Bain & Company. These re-appointments ensure leadership continuity within the promoter family, as both are sons of the Chairman and Co-Chairman respectively.
Key Highlights
Re-appointment of Mr. Priyavrat Bhartia as MD for a 3-year term effective June 1, 2026
Re-appointment of Mr. Arjun Shanker Bhartia as Joint MD for a 3-year term effective June 1, 2026
Mr. Priyavrat Bhartia has 29 years of industry experience and an MBA from Stanford University
Mr. Arjun Shanker Bhartia is a Brown University graduate with previous experience at Bain & Company
Both appointments are subject to the final approval of the company's shareholders
👀 What to Watch
Investors should view this as a move for leadership stability and continuity of the current strategic direction. No immediate action is required as this is a routine re-appointment of existing promoter-group leadership.
Jubilant Pharmova Recommends 500% Dividend of Rs 5 Per Share; Sets July 24 as Record Date
Jubilant Pharmova's Board has recommended a final dividend of Rs 5 per equity share for the financial year ended March 31, 2026, representing a 500% payout on its Re 1 face value. The company has officially fixed July 24, 2026, as the record date to determine shareholder eligibility for this payment. This announcement accompanied the release of the company's audited financial results, which received an unmodified opinion from statutory auditors Walker Chandiok & Co LLP. The dividend is subject to shareholder approval at the upcoming Annual General Meeting.
Key Highlights
Recommended a final dividend of 500% amounting to Rs 5 per equity share of face value Re 1.
Fixed Friday, July 24, 2026, as the record date for the purpose of final dividend payment.
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Statutory auditors issued an unmodified opinion, confirming the accuracy of the financial statements.
Dividend payment will be processed within 30 days from the date of the Annual General Meeting.
👀 What to Watch
Investors seeking dividend income should ensure they hold the shares before the July 24 record date to be eligible for the Rs 5 per share payout. The clean audit report further reinforces confidence in the company's reported financial performance.
Jubilant Pharmova Recommends Rs 5 Final Dividend; Sets Record Date for July 24, 2026
Jubilant Pharmova's Board of Directors has recommended a final dividend of Rs 5 per equity share for the financial year ended March 31, 2026, representing a 500% payout on the face value of Re 1. The company has officially fixed July 24, 2026, as the record date to determine shareholder eligibility for this payout. This announcement accompanied the approval of the company's audited financial results for FY26, which received an unmodified opinion from statutory auditors. The dividend remains subject to shareholder approval at the upcoming Annual General Meeting.
Key Highlights
Recommended a final dividend of Rs 5 per equity share (500% of face value)
Fixed July 24, 2026, as the record date for the purpose of dividend payment
Approved audited standalone and consolidated financial results for FY ended March 31, 2026
Statutory auditors Walker Chandiok & Co LLP issued an unmodified opinion on financial results
Dividend to be dispatched within 30 days from the date of the Annual General Meeting
👀 What to Watch
Investors seeking dividend yield should note the record date of July 24, 2026, to ensure eligibility. While the dividend is a positive signal of cash flow, investors should also review the detailed FY26 earnings for long-term growth prospects.
Jubilant Pharmova Re-appoints Priyavrat Bhartia as MD and Arjun Bhartia as Joint MD for 3 Years
The Board of Jubilant Pharmova has approved the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director for a further term of three years, effective June 1, 2026. Mr. Priyavrat Bhartia, aged 49, brings 29 years of industry experience and an MBA from Stanford, while Mr. Arjun Bhartia, aged 39, has a background in consulting with Bain & Company. These re-appointments ensure management continuity for the company's strategic operations. The appointments are subject to the final approval of the company's shareholders.
Key Highlights
Re-appointment of Mr. Priyavrat Bhartia as Managing Director for a 3-year term starting June 1, 2026
Re-appointment of Mr. Arjun Shanker Bhartia as Joint Managing Director for a 3-year term starting June 1, 2026
Mr. Priyavrat Bhartia possesses 29 years of industry experience and an MBA from Stanford University
Mr. Arjun Shanker Bhartia is a Brown University graduate with prior experience at Bain & Company
Both re-appointments are subject to the approval of the company's shareholders
👀 What to Watch
Investors should view this as a move for management stability and continuity. No immediate action is required as the leadership remains unchanged and aligned with the current long-term strategy.
Jubilant Foodworks Q4 FY26: Consolidated Revenue Up 19.3% YoY, PAT Surges 67.3%
Jubilant Foodworks reported a robust consolidated performance for Q4 FY26, with revenue reaching ₹24,995 million, a 19.3% YoY increase. Consolidated PAT from continued operations jumped 67.3% YoY to ₹936 million, supported by a 69 bps expansion in EBITDA margins to 19.4%. While India standalone revenue grew 6.4% with a modest 0.2% LFL growth for Domino's, the company saw a strong 10.4% YoY growth in orders. The global store network expanded to 3,636 stores, with 351 net additions during FY26.
Key Highlights
Consolidated Revenue for Q4 FY26 grew 19.3% YoY to ₹24,995 mn; FY26 Revenue stood at ₹95,125 mn.
Consolidated PAT from continued operations surged 67.3% YoY to ₹936 mn in Q4 FY26.
Domino's India recorded 10.4% YoY order growth, though LFL growth was muted at 0.2% for the quarter.
Popeyes India demonstrated strong momentum with 28% SSG in FY26, reaching a total of 78 stores.
Free Cashflow to Firm (FCFF) for the consolidated entity improved to ₹2,472 mn in FY26 from ₹2,422 mn in FY25.
👀 What to Watch
Investors should note the strong consolidated growth and margin improvement despite soft LFL growth in the domestic Domino's business. The rapid scaling of Popeyes and strong performance in international markets like Turkey provide significant growth diversification.
Jubilant Foodworks Q4 FY26: Consolidated PAT Surges 67.3% YoY, Revenue Up 19.3%
Jubilant Foodworks reported a robust Q4 FY26 with consolidated revenue reaching ₹24,995 million, a 19.3% YoY increase, and a significant 67.3% jump in PAT to ₹936 million. For the full year FY26, Domino's India maintained a steady 6.5% like-for-like (LFL) growth, while Popeyes emerged as a major growth driver with 28% same-store sales growth. International operations showed exceptional strength, particularly in Turkey where revenue grew 59.2% and PAT rose 150% in Q4. The company expanded its global footprint to 3,636 stores, adding 351 net stores during the fiscal year.
Key Highlights
Consolidated Q4 Revenue grew 19.3% YoY to ₹24,995 million with EBITDA margins expanding 69 bps to 19.4%.
Domino's India delivered 6.5% LFL growth in FY26; delivery order volumes grew in high teens during Q4.
Popeyes India recorded 28% same-store sales growth in FY26, showing strong traction in the fried chicken category.
International business momentum was high with Turkey PAT growing 150% YoY and Sri Lanka/Bangladesh turning EBITDA positive.
Global network reached 3,636 stores with 289 net additions in India alone during FY26.
👀 What to Watch
Investors should view the strong performance of Popeyes and the international segment as positive diversifiers to the core Domino's business. The company's focus on technology-led efficiency and aggressive store expansion supports a long-term growth outlook despite temporary domestic LFL moderation.
Jubilant Foodworks Recommends Rs 1.2 Dividend per Share for FY26
Jubilant Foodworks' Board has recommended a dividend of Rs 1.2 per equity share for the financial year ended March 31, 2026. This represents a 60% payout on the face value of Rs 2 per share. The dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM). The company also approved its audited standalone and consolidated financial results for the year with an unmodified audit opinion.
Key Highlights
Recommended dividend of INR 1.2 per equity share for FY 2025-26
Dividend payout ratio stands at 60% of the face value of INR 2 per share
Audited financial results for the year ended March 31, 2026, approved with an unmodified opinion
Dividend to be paid within 30 days of approval at the Annual General Meeting
👀 What to Watch
Investors should monitor the upcoming AGM date for the record date and dividend payment timeline. The unmodified audit report confirms the reliability of the financial statements.
Jubilant Foodworks Approves FY26 Results, Recommends INR 1.2 Dividend Per Share
Jubilant Foodworks has approved its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The Board of Directors has recommended a final dividend of INR 1.2 per equity share, which is 60% of the face value of INR 2. The statutory auditors, Deloitte Haskins & Sells LLP, have issued an unmodified opinion on the financial statements, indicating no major accounting concerns. The dividend is subject to shareholder approval at the upcoming Annual General Meeting and will be paid within 30 days of that meeting.
Key Highlights
Board recommended a final dividend of INR 1.2 per equity share (60% of face value) for FY 2025-26.
Audited Standalone and Consolidated Financial Results for the year ended March 31, 2026, were approved.
Auditors issued an unmodified opinion, confirming the accuracy and fairness of the financial disclosures.
The Board meeting was conducted on May 20, 2026, concluding within 45 minutes.
👀 What to Watch
Investors should monitor the detailed financial statements for same-store sales growth (SSSG) and margin performance in the QSR segment. The recommended dividend provides a modest yield, but the long-term outlook depends on the company's expansion strategy and input cost management.
